´ëÇÑ°¨¿°ÇÐȸ (¿Â¶óÀÎ) ICIC 2021 (5th Interscience Conference of Infection and Chemotherapy) 2ÀÏÂ÷ : 2021-11-05±³À°ÀÏÀÚ : 2021-11-05
±³À°Àå¼Ò : ¿Â¶óÀÎ LIVE
±³À°ÁÖÁ¦ :
(¿Â¶óÀÎ) ICIC 2021 (5th Interscience Conference of Infection and Chemotherapy) 2ÀÏÂ÷ÁÖÃÖ±â°ü : ´ëÇÑ°¨¿°ÇÐȸ
´ã´çÀÚ : ´ëÇÑ°¨¿°ÇÐȸ
¿¬¶ôó : 02-2055-1441
À̸ÞÀÏ :
ksinfect@ksid.or.kr ±³À°Á¾·ù : ³»°ú, ¿µ»óÀÇÇаú, °áÇÙ°ú, Áø´Ü°Ë»çÀÇÇаú, º´¸®°ú
Âü¼®¿¹»óÀοø : 500¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 8 ½Ã°£ 20ºÐ
¼¼ºÎ¼ö°·á : 120,000¿ø
ºñ°í Á¤È¸¿ø Àü¹®ÀÇ 100,000 Àü°øÀÇ 60,000 Çлý 40,000ºñȸ¿ø Àü¹®ÀÇ 120,000 Àü°øÀÇ 80,000 Çлý 50,000
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 11-05 ·Ôµ¥È£ÅÚ¿ùµå 07:30~07:55 Clinical research from healthcare Big-data : practice and perspective ¼±âÇö(½ÉÆò¿ø)
±³À°½Ã°£ 11-05 ·Ôµ¥È£ÅÚ¿ùµå 07:55~08:20 Investigator initiated trials made easy : A to Z ¹Ú¿Ï¹ü(¼¿ïÀÇ´ë)
ÈÞ½Ä 11-05 ·Ôµ¥È£ÅÚ¿ùµå 08:20~08:30 Break ()
±³À°½Ã°£ 11-05 ·Ôµ¥È£ÅÚ¿ùµå 08:30~09:20 Addressing unmet needs in pneumonia: moving beyond culture with molecular diagnostics Tristan Timbrook(bioMerieux)
ÈÞ½Ä 11-05 ·Ôµ¥È£ÅÚ¿ùµå 09:20~09:30 Break ()
±³À°½Ã°£ 11-05 ·Ôµ¥È£ÅÚ¿ùµå 09:30~10:00 SARS-CoV-2 infection in pregnancy: considerations for the mother and child ±èÀǼ®(¼¿ïÀÇ´ë)
±³À°½Ã°£ 11-05 ·Ôµ¥È£ÅÚ¿ùµå 10:00~10:30 COVID-19 vaccination for children and adolescents ÃÖ¿µÁØ(°í·ÁÀÇ´ë)
±³À°½Ã°£ 11-05 ·Ôµ¥È£ÅÚ¿ùµå 10:30~11:00 How long dose immunity last after COVID-19 or Vaccination? ³ëÁöÀ±(°í·ÁÀÇ´ë)
ÈÞ½Ä 11-05 ·Ôµ¥È£ÅÚ¿ùµå 11:00~11:20 Break ()
±³À°½Ã°£ 11-05 ·Ôµ¥È£ÅÚ¿ùµå 11:20~12:10 Microbiome and Infectious diseases ±èÁöÇö(¿¬¼¼´ë)
ÈÞ½Ä 11-05 ·Ôµ¥È£ÅÚ¿ùµå 12:10~12:30 Break ()
±³À°½Ã°£ 11-05 ·Ôµ¥È£ÅÚ¿ùµå 12:30~13:20 The Past and Present of Pneumococcal Conjugate Vaccine Protection for Adults : Prevenar13 ±èÅÂÇü(¼øõÇâÀÇ´ë)
ÈÞ½Ä 11-05 ·Ôµ¥È£ÅÚ¿ùµå 13:20~13:30 Break ()
±³À°½Ã°£ 11-05 ·Ôµ¥È£ÅÚ¿ùµå 13:30~13:40 Association between initial viral load and outcome of patients with severe fever with thrombocytopenia Áø¼Ö(¼¿ï¾Æ»êº´¿ø)
±³À°½Ã°£ 11-05 ·Ôµ¥È£ÅÚ¿ùµå 13:40~13:50 The immunogenicity and protective efficacy of MMR vaccine among healthcare workers ¼®Çý¸®(°í·ÁÀÇ´ë)
±³À°½Ã°£ 11-05 ·Ôµ¥È£ÅÚ¿ùµå 13:50~14:00 Need for a third dose of measles containing vaccine among young-aged healthcare workers in measles elimination setting ±è¿ëÂù(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 11-05 ·Ôµ¥È£ÅÚ¿ùµå 14:00~14:10 Time trends in cancer incidence among people living with HIV/AIDS, 2007-2018: A nationwide population-based study Á¤¿ì¿ë(ÀÏ»ê°ø´Üº´¿ø)
±³À°½Ã°£ 11-05 ·Ôµ¥È£ÅÚ¿ùµå 14:10~14:20 Population pharmacokinetics of piperacillin-tazobactam in critically ill Korean patients and the effects of extracorporeal membrane oxygenation ±è¿ë±Õ(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 11-05 ·Ôµ¥È£ÅÚ¿ùµå 14:20~14:30 Letermovir prophylaxis for cytomegalovirus in allogeneic hematopoietic stem cell transplantation recipients: a retrospective study at a single center in Korea ³ë´öÈñ(°¡Å縯ÀÇ´ë)
ÈÞ½Ä 11-05 ·Ôµ¥È£ÅÚ¿ùµå 14:30~14:40 Break ()
±³À°½Ã°£ 11-05 ·Ôµ¥È£ÅÚ¿ùµå 14:40~14:50 Äڷγª19 À¯Çà¿¡ µû¸¥ ±¹³» º´¿ø¿¡¼ÀÇ Ç×»ýÁ¦ »ç¿ë ÆÐÅÏ º¯È ºÐ¼® ±èºÀ¿µ(ÇѾçÀÇ´ë)
±³À°½Ã°£ 11-05 ·Ôµ¥È£ÅÚ¿ùµå 14:50~15:00 The impact of a multidisciplinary antimicrobial stewardship on antimicrobial consumption and factors affecting compliance to recommendations: A quasi-experimental study À¯Áø¼¼(¾ÆÁÖÀÇ´ë)
±³À°½Ã°£ 11-05 ·Ôµ¥È£ÅÚ¿ùµå 15:00~15:10 »ó±ÞÁ¾ÇÕº´¿øÀÇ Ç×»ýÁ¦ ½ºÆ©¾îµå½Ê ÇÁ·Î±×·¥ÀÇ ´Ü°èÀû È®´ë°¡ Ç×»ýÁ¦ »ç¿ë ¹× ³»¼º·ü¿¡ ¹ÌÄ¡´Â ¿µÇ⠺м® ½Åµ¿ÈÆ(¼¿ïÀÇ´ë)
±³À°½Ã°£ 11-05 ·Ôµ¥È£ÅÚ¿ùµå 15:10~15:20 Ç÷¾×³»°úº´µ¿ÀÇ Áø±Õ Æ÷ÀÚ ³óµµ °ø±â ¹è¾ç °á°ú Á¶À縲(¼¿ï¾Æ»êº´¿ø)
±³À°½Ã°£ 11-05 ·Ôµ¥È£ÅÚ¿ùµå 15:20~15:30 Risk factors of Clostridioides Difficile toxin retainments in hospitalized patients who are older than 65 years with infectious disease through CD toxin PCR screening test at the time of admission. À̱⺴(°í·ÁÀÇ´ë)
±³À°½Ã°£ 11-05 ·Ôµ¥È£ÅÚ¿ùµå 15:30~15:40 Clinical and microbiological characteristics of, and risk factors for bloodstream infections among patients with extracorporeal membrane oxygenation ÀÌÀºÈ(¿¬¼¼ÀÇ´ë)
ÈÞ½Ä 11-05 ·Ôµ¥È£ÅÚ¿ùµå 15:40~16:00 Break ()
±³À°½Ã°£ 11-05 ·Ôµ¥È£ÅÚ¿ùµå 16:00~16:30 Implementation of NGS into clinical diagnosis of infectious diseases È«±âÈ£(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 11-05 ·Ôµ¥È£ÅÚ¿ùµå 16:30~17:00 Antibiotics dosing on special situations: RRT, ECMO, etc ±è¿ë±Õ(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 11-05 ·Ôµ¥È£ÅÚ¿ùµå 17:00~17:30 Antimicrobial stewardship in immunocompromised patients ÀÌ»ó¿À(¿ï»êÀÇ´ë)